News - Pharmaphorum

Latest News

in News News
NICE in talks with Biogen after rejecting SMA drug
August 14, 2018 Share
X
NICE in talks with Biogen after rejecting SMA drug
https://pharmaphorum.com/news/nice-in-talks-with-biogen-after-rejecting-sma-drug/
in News News
Breakthrough designation for Roche/Novartis’ Xolair in food allergies
August 14, 2018 Share
X
Breakthrough designation for Roche/Novartis’ Xolair in food allergies
https://pharmaphorum.com/news/breakthrough-designation-for-roche-novartis-xolair-in-food-allergies/

Amicus’ oral Fabry disease drug approved in US

Decision follows approval in Europe

Amicus’ oral Fabry disease drug approved in US

https://pharmaphorum.com/news/amicus-oral-fabry-disease-drug-approved/

Astellas buys eye gene therapy biotech Quethera for $109m

Japanese Astellas Pharma has bought privately-owned biotech Quethera for $109 million, gaining access to its gene therapy focused

Astellas buys eye gene therapy biotech Quethera for $109m

https://pharmaphorum.com/news/astellas-expands-ocular-gene-therapy-investment/

Alnylam’s Onpattro is first ever FDA-approved RNAi drug

Onpattro will cost $450,000 a year

Alnylam’s Onpattro is first ever FDA-approved RNAi drug

https://pharmaphorum.com/news/alnylams-onpattro-first-ever-approved-rnai-drug/

See all

More news

Sarepta dives deeper into gene therapy

Sarepta Therapeutics has handed $30 million to Lacerta in exchange for a group of gene therapies, including a

Sarepta dives deeper into gene therapy

https://pharmaphorum.com/news/sarepta-dives-deeper-gene-therapy/

CF patients furious as Vertex turns back on NICE

Patients in England could be denied access to drug

CF patients furious as Vertex turns back on NICE

https://pharmaphorum.com/news/cf-patients-furious-as-vertex-turns-back-on-nice/

FDA approves generic under new strategy to boost competition

The US regulator has approved a drug to treat low potassium as the first generic with the Competitive

FDA approves generic under new strategy to boost competition

https://pharmaphorum.com/news/fda-approved-hypokalymia-generic-cgt/

Concerns over Teva migraine drug because of manufacturing issues

There are concerns that launch of Teva’s migraine drug may be delayed because of issues uncovered by the

Concerns over Teva migraine drug because of manufacturing issues

https://pharmaphorum.com/news/concerns-over-teva-migraine-drug-because-of-manufacturing-issues/

AZ considers options as US gout drug deal backfires

Ironwood tears up licensing agreement after sales disappoint

AZ considers options as US gout drug deal backfires

https://pharmaphorum.com/news/az-considers-options-drug-deal-backfires/

Pain Therapeutics’ opioid drug fails to gain FDA approval

The US regulator has rejected Pain Therapeutics’ abuse-deterrent opioid painkiller drug, Remoxy, for the fourth time. In a

Pain Therapeutics’ opioid drug fails to gain FDA approval

https://pharmaphorum.com/news/opioid-drug-fails-gain-fda-approval/

Prudential and Babylon join forces in Asia

Global insurance giant Prudential signed an exclusive agreement to use Babylon Health’s artificial intelligence (AI) based healthcare application

Prudential and Babylon join forces in Asia

https://pharmaphorum.com/news/prudential-babylon-join-forces-asia/

NHS faces legal action over fertility treatment for gender transitioning patients

England’s NHS must offer transgender patients awaiting transitioning treatment access to fertility services, or face legal action according

NHS faces legal action over fertility treatment for gender transitioning patients

https://pharmaphorum.com/news/nhs-fertility-treatment-gender-transitioning-patients/

Almirall buys Allergan’s derma portfolio

Almirall is expanding its business by buying Allergan’s dermatology portfolio. The Spanish pharma company will buy five brands

Almirall buys Allergan’s derma portfolio

https://pharmaphorum.com/news/almirall-buys-allergans-derma-portfolio/

Takeda finalises buyout of TiGenix

Japanese pharma giant Takeda has completed its buyout of TiGenix. Takeda’s main R&D focus is in oncology, gastroenterology

Takeda finalises buyout of TiGenix

https://pharmaphorum.com/news/japanese-takeda-finalises-tigenix-boyout/

FDA grants leukaemia drug ‘breakthrough’ status

A leukaemia drug has been granted ‘breakthrough therapy’ status by the US drug regulator. Daiichi Sankyo announced that

FDA grants leukaemia drug ‘breakthrough’ status

https://pharmaphorum.com/market-access-2/fda-grants-leukaemia-drug-breakthrough-status/

NHS saved £324 million by switching to biosimilars and generics

The UK’s national healthcare provider saved £324 million by switching its patients to “better value” biosimilar and generic

NHS saved £324 million by switching to biosimilars and generics

https://pharmaphorum.com/news/nhs-saved-millions-switching-biosimilars/

The first lipodystrophy treatment for European patients

Novelion Therapeutics’ Myalepta (metreleptin) developed for the ultra-rare condition lipodystrophy has been approved by the European Commission, giving

The first lipodystrophy treatment for European patients

https://pharmaphorum.com/news/the-first-lipodystrophy-treatment-for-european-patients/

Pfizer wins Herceptin biosimilar approval in Europe

European Commission (EC) has approved Pfizer’s Trazimera, for breast and gastric cancer treatment, marking it as pharma’s first

Pfizer wins Herceptin biosimilar approval in Europe

https://pharmaphorum.com/news/herceptin-biosimilar-european-approval/

LEO Pharma acquires Bayer’s dermatology unit

Danish LEO Pharma announced yesterday (July 31st) that it has entered a binding agreement to purchase Bayer’s global

LEO Pharma acquires Bayer’s dermatology unit

https://pharmaphorum.com/news/leo-pharma-acquires-bayers-dermatology-unit/

Search

Advanced Search

Trending

Latest News

More news